1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
LortetTieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hamoir M, Schmitz S and Gregoire V: The
role of neck dissection in squamous cell carcinoma of the head and
neck. Curr Treat Options Oncol. 15:611–624. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
|
5
|
AbdElsalam EA and Ismaeil NA:
Melanoma-associated antigen genes: A new trend to predict the
prognosis of breast cancer patients. Med Oncol. 31:2852014.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Laban S, Atanackovic D, Luetkens T, Knecht
R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A,
et al: Simultaneous cytoplasmic and nuclear protein expression of
melanoma antigen-A family and NY-ESO-1 cancer-testis antigens
represents an independent marker for poor survival in head and neck
cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Li G, Song P and Zhang B: Expression and
significance of MAGE genes in human lung cancer. Zhongguo Fei Ai Za
Zhi. 16:308–313. 2013.PubMed/NCBI
|
8
|
Monte M, Simonatto M, Peche LY, Bublik DR,
Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor
antigens target p53 transactivation function through histone
deacetylase recruitment and confer resistance to chemotherapeutic
agents. Proc Natl Acad Sci USA. 103:11160–11165. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hartmann S, Kriegebaum U, Küchler N,
Brands RC, Linz C, Kübler AC and Müller-Richter UD: Correlation of
MAGE-A tumor antigens and the efficacy of various chemotherapeutic
agents in head and neck carcinoma cells. Clin Oral Investig.
18:189–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hartmann S, Kriegebaum U, Küchler N,
Lessner G, Brands RC, Linz C, Schneider T, Kübler AC and
Müller-Richter UD: Efficacy of cetuximab and panitumumab in oral
squamous cell carcinoma cell lines: Prognostic value of MAGE-A
subgroups for treatment success. J Craniomaxillofac Surg.
41:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Xia LP, Xu M, Chen Y and Shao WW:
Expression of MAGE-A11 in breast cancer tissues and its effects on
the proliferation of breast cancer cells. Mol Med Rep. 7:254–258.
2013.PubMed/NCBI
|
12
|
Minges JT, Su S, Grossman G, Blackwelder
AJ, Pop EA, Mohler JL and Wilson EM: Melanoma antigen-A11
(MAGE-A11) enhances transcriptional activity by linking androgen
receptor dimers. J Biol Chem. 288:1939–1952. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ries J, Agaimy A, Vairaktaris E, Gorecki
P, Neukam FW, Strassburg LH and Nkenke E: Detection of MAGE-A
expression predicts malignant transformation of oral leukoplakia.
Cancer Invest. 30:495–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Krauss E, Rauthe S, Gattenlöhner S,
Reuther T, Kochel M, Kriegebaum U, Kübler AC and Müller-Richter UD:
MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig.
15:315–320. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Greene FL, Page DL, Fleming ID, Fritz A,
Balch CM, Haller DG and Morrow M: AJCC cancer staging manual. 6th
edition. Springer; New York: 2002, View Article : Google Scholar
|
16
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
17
|
Hildebrand LC, Carvalho AL, Lauxen IS, Nör
JE, Cerski CT and Sant'Ana Filho M: Spatial distribution of cancer
stem cells in head and neck squamous cell carcinomas. J Oral Pathol
Med. 43:499–506. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lindberg P, Larsson A and Nielsen BS:
Expression of plasminogen activator inhibitor-1, urokinase receptor
and laminin gamma-2 chain is an early coordinated event in
incipient oral squamous cell carcinoma. Int J Cancer.
118:2948–2956. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ries J, SchultzeMosgau S, Neukam F, Diebel
E and Wiltfang J: Investigation of the expression of melanoma
antigen-encoding genes (MAGE-A1 to-A6) in oral squamous cell
carcinomas to determine potential targets for gene-based cancer
immunotherapy. Int J Oncol. 26:817–824. 2005.PubMed/NCBI
|
20
|
van den Brand M, Takes RP,
Blokpoel-deRuyter M, Slootweg PJ and van Kempen LC: Activated
leukocyte cell adhesion molecule expression predicts lymph node
metastasis in oral squamous cell carcinoma. Oral Oncol. 46:393–398.
2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
MullerRichter UD, Dowejko A, Reuther T,
Kleinheinz J, Reichert TE and Driemel O: Analysis of expression
profiles of MAGE-A antigens in oral squamous cell carcinoma cell
lines. Head Face Med. 5:102009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Voskens CJ, Sewell D, Hertzano R, DeSanto
J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B,
et al: Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines
in patients with head and neck carcinoma. Head Neck. 34:1734–1746.
2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zandberg DP, Rollins S, Goloubeva O,
Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ,
Zimrin A, et al: A phase I dose escalation trial of MAGE-A3-and
HPV16-specific peptide immunomodulatory vaccines in patients with
recurrent/metastatic (RM) squamous cell carcinoma of the head and
neck (SCCHN). Cancer Immunol Immunother. 64:367–379. 2015.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Han L, Jiang B, Wu H, Zhang S and Lu X:
Expression and prognostic value of MAGE-A9 in laryngeal squamous
cell carcinoma. Int J Clin Exp Pathol. 7:6734–6742. 2014.PubMed/NCBI
|
25
|
Hartmann S, Brands RC, Küchler N, Fuchs A,
Linz C, Kübler AC and Müller-Richter UD: Melanoma-associated
antigen expression and the efficacy of tyrosine kinase inhibitors
in head and neck cancer. Oncol Lett. 10:1211–1217. 2015.PubMed/NCBI
|
26
|
Wilson EM: Androgen receptor molecular
biology and potential targets in prostate cancer. Ther Adv Urol.
2:105–117. 2010. View Article : Google Scholar : PubMed/NCBI
|